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methacin should be used in addition to pancre­
atic stents in high­risk patients. However, post 
hoc analysis of our trial suggests that indometha­
cin may obviate the need for prophylactic pan­
creatic stent placement (unpublished data), and 
we therefore agree with Baron et al. that com­
parative effectiveness studies of indomethacin 
and pancreatic stenting are necessary.
In response to Crippa et al.: we enrolled pa­
tients at high risk for post­ERCP pancreatitis 
(with clinical suspicion of sphincter of Oddi 
dysfunction in >80% and pancreatography per­
formed in >85%), whereas Sotoudehmanesh et 
al. enrolled mostly low­risk patients (with clini­
cal suspicion of sphincter of Oddi dysfunction in 
8% and pancreatography performed in 18%).1 
This difference in study samples almost cer­
tainly accounts for the difference in post­ERCP 
pancreatitis rates between the two trials in both 
the indomethacin group and the placebo group. 
Nevertheless, we agree that it remains unclear 
whether administration of rectal indomethacin 
before or after ERCP is most effective; current 
guidelines support the use of either approach.2 
Studies addressing the clinical pharmacology of 
prophylactic indomethacin, including timing and 
dosage, are needed.
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More on Treatment for Acute Anterior Cruciate Ligament Tears
To the Editor: We previously published results 
of our randomized trial of treatment for anterior 
cruciate ligament tears (July 22, 2010, issue).1 In 
Table 3 of that article, which shows primary, sec­
ondary, and exploratory outcomes at 2 years, the 
P values and confidence intervals were calculated 
in compliance with the “Points to Consider on 
Adjustment for Baseline Covariates,” in the Euro­
pean Medicines Agency guidelines a distinction 
that was not stated in the article. Accordingly, 
the P values were adjusted for baseline value, 
whereas the unadjusted confidence intervals 
were calculated by maximum­likelihood estima­
tion. There were no significant between­group 
differences in either the adjusted analysis or the 
unadjusted analysis, and thus the difference be­
tween the two results does not affect our conclu­
sions. In order to clarify our results, we have 
provided a table that includes the unadjusted 
P values and the adjusted 95% confidence inter­
vals in the Supplementary Appendix, available 
with the full text of this letter at NEJM.org.
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Alopecia Areata
To the Editor: In their review article on alope­
cia areata, Gilhar et al. (April 19 issue)1 do not 
mention psoralen–ultraviolet A (PUVA) photo­
chemotherapy. This was probably because there 
have been no published controlled studies of this 
local immunosuppressive treatment for extensive 
alopecia areata.2 However, reported response 
rates are typically as good as those for contact 
immunotherapy, which is supported by only 
slightly better evidence, with half­scalp compara­
tive studies confirming an effect.3 Contact im­
munotherapy involves the discomfort of a medi­
cally induced dermatitis every week; PUVA only 
rarely causes localized phototoxic responses. In 
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